• Atomo receives additional FebriDx Pascal orders totaling $495k
• Atomo secures a $500k order for HIV Self-Test for supply to an African country
• Atomo signs an exclusive global licensing agreement for a novel Liver function test on Pascal

Atomo Diagnostics Limited (ASX: AT1) has reported its quarterly activities and cash flow report for Q2 FY26. Key highlights include:- Atomo receives additional FebriDx Pascal orders totaling $495k, with a decision on FebriDx CLIA waiver expected in early 2026. The company also commences an operational expansion program.- Atomo secures a $500k order for HIV Self-Test for supply to an African country, funded by the Global Fund.- Atomo signs an exclusive global licensing agreement for a novel Liver function test on Pascal, with the first targeted application being monitoring drug treatments with known Drug Induced Liver Injury risk. The test is currently under evaluation by a large multinational pharmaceutical company in a US drug trial.- Atomo secures new international customers, including a UK customer with an initial order for 20,000 Pascal cassettes and a Canadian customer with a paid development complete and a commercial quantity of cassettes pending.- Revenue generated during the quarter was $1.5m, up 121% on the previous quarter, with strong growth in HIV ($600k) and OEM ($820k) products. Gross margin remained steady at 40%.- Cash on hand as at 31 December 2025 was $3.51m, with cash receipts for the quarter totaling $2.2m.- The company's key proprietary asset, the Blister Machine-mk2, has been relocated to an Atomo operated facility in Sydney, increasing capacity and strengthening operational oversight.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.

The company did not provide any forward-looking outlook statements in the announcement.